Galectin Therapeutics Inc.
Every calculator, already run for GALT
Open the full toolkit →You have the numbers on GALT. Get the argument.
A written report on which of these readings actually decide the outcome for Galectin Therapeutics Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
1 analysts covering GALTOwnership & short interest
Insider Trading Activity for GALT
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Galectin Therapeutics Inc.
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc. to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011…
GALT — frequently asked
Is GALT a buy right now?
Wall Street's consensus rating on Galectin Therapeutics Inc. is none across 1 analysts, with a mean price target of $11.00 (+183% vs. the current $3.89). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Compare Galectin Therapeutics Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Galectin Therapeutics Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full GALT research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Galectin Therapeutics Inc., in minutes. 3 free reports included with every account — no credit card required.